Category Archives: OTC

Bingo Nation, Inc. (BLTO: OTCQB) | Bingo Nation Announces Board Appointment

LAS VEGAS, March 22, 2017 (GLOBE NEWSWIRE) — Bingo Nation Inc. (OTC:BLTO.QB) (the “Company”) is pleased to announce the appointment of Richard G. Hill to its Board of Directors. 

Hill, age 64, served as chairman of the Oneida Nation of Wisconsin from 2008 to 2001.  He previously served as chairman from 1990-1993. Under Hill’s first term as chairman, Oneida signed its first gaming compact with the State of Wisconsin.

From 1993 to 2001 Hill also served as chairman of the National Indian Gaming Association (NIGA). Based in Washington, D.C., NIGA is a non-profit organization that has grown to 184 Indian tribes, representing the interests of tribal gaming enterprises. Under Hill’s leadership, NIGA became a nationally recognized voice on Indian gaming on legislative and entrepreneurial issues and established regulatory standards and policies for tribal governmental gaming nationwide. As the main national public relations spokesperson for the organization,  Hill addressed the National Press Club, Harvard Law School, Arizona State Law School, and a variety of national and regional trade shows and other prestigious entities, encouraging Indian self-sufficiency, self-regulation, and integrity for gaming enterprises.

In October 2001 Hill became the first Gaming Hall of Fame inductee from the Indian gaming segment.  He was recognized for his significant role in nurturing growth of tribal gaming.  That Industry has now expanded into 497 gaming establishments operated by 244 tribes across 29 states.

Since 2001 a NIGA Chairman Emeritus, Hill formed The Hill Group LLC, to consult with various entities to identify economic development projects and partnerships in Indian Country along with equity/debt projects. He also formed RGH Holdings Inc., to assist and develop real estate both on and off reservations, including the development of the first ever off-reservation, tribal consortium hotel investment, located in Washington, D.C. The Residence Inn by Marriott where RGH identified and negotiated the $12 million tribal equity participation is a $42 million extended-stay hotel project.

David Matheson commented: “We are pleased to welcome and honored to have Rick join the Board.  He is to my knowledge not only well-respected but a true team builder throughout Indian Country.  He is without doubt our greatest ambassador having served as a prominent leader in the development of tribal gaming for over three decades.”

About Bingo Nation

Bingo Nation specializes in tribal gaming, freemium marketing, lottery and interactive technology-based products focused on building memorable brand experiences and more attainable jackpots with better entertainment value. Our portfolio includes innovative proxy-player tribal gaming management, interactive advertising, and game sales via self-serve kiosks, smart phones, and tracking via secure cloud-based customer accounting systems.  For more information, please visit BingoNationUSA.com.

Bingo Nation Inc.
info@bingonationusa.com
Tel: (888) 475 4098

Article source: http://www.otcmarkets.com/stock/BLTO/news?id=154047

CohBar Inc. (CWBR: OTCQX U.S.) | CohBar, Inc. Announces Fourth Quarter 2016 Financial Results

CohBar, Inc. Announces Fourth Quarter 2016 Financial Results

Mar 22, 2017

OTC Disclosure News Service

CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), a preclinical stage
biotechnology company focused on developing mitochondria based
therapeutics (MBTs) to treat age-related diseases, today reported
financial results for the fourth quarter ended December 31, 2016 and
provided an update on the Company’s preclinical development program.

“Our development team initiated IND-enabling studies for our lead drug
candidates CB4209 and CB4211 in 2016, with the goal of commencing our
first human clinical trial in early 2018,” said Simon Allen, CohBar’s
CEO. “In addition, we continued to see positive preclinical activity for
our lead programs, including our latest STAM data, validating the
therapeutic potential of our drug candidates in the treatment of NASH as
well as obesity. We also made tremendous progress mining the
mitochondrial genome for new peptides with biological activity using our
proprietary technology platform, and filed multiple new provisional
patent applications for our discoveries, further expanding our research
pipeline and MBT opportunities.”

Fourth Quarter 2016 and Recent Preclinical Development and Business
Highlights

  • Completed preclinical studies for our lead program that support
    NASH as a potential clinical indication for development.
    Following
    the selection of its two lead drug candidates CB4209 and CB4211 in
    September 2016, CohBar completed a preclinical study in January 2017
    that investigated the therapeutic effects of its two drug candidates
    in the widely used STAM mouse model for non-alcoholic steatohepatitis,
    or NASH, a severe form of fatty liver disease. In this model,
    treatment with either CB4209 or CB4211 resulted in a significant
    reduction of the non-alcoholic fatty liver disease (NAFLD) activity
    score, or NAS, a composite measure of steatosis (fat accumulation),
    inflammation and hepatocyte ballooning (cellular injury). The results
    from this STAM study support findings from CohBar’s earlier
    preclinical studies of its lead compounds in diet induced obesity
    (DIO) models, which showed significant decreases in liver fat and
    favorable reductions in biomarkers associated with NASH. Additional
    efficacy studies of CB4209 and CB4211 are ongoing or planned. CohBar
    plans to submit the preclinical DIO and NASH data during 2017 for
    presentation at a major liver-focused scientific meeting.
  • Discovered new biologically active peptides in the mitochondrial
    genome and expanded intellectual property portfolio.
    In line with
    the Company’s strategy to discover, identify and optimize all
    biologically active peptides encoded within the mitochondrial genome,
    CohBar’s scientists identified a large number of new mitochondrial
    peptides with biological activity and the Company filed over 50 new
    provisional patent applications related to these peptides and their
    analogs.
  • Expanded investment community outreach to build awareness. During
    the fourth quarter and early 2017, CohBar’s management continued to
    meet with existing and potential investors in multiple non-deal
    roadshows and at investment conferences in the U.S. and Canada. In
    addition, CohBar’s CEO Simon Allen presented at several investment
    conferences including the 15th Annual BIO Investor Forum in
    San Francisco in October 2016, the 9th Annual Biotech
    Showcase in San Francisco in January 2017, the OTCQX Virtual
    Conference in February 2017, and the BIO CEO Investor Conference in
    New York in February 2017.

During the fourth quarter, CohBar’s founders continued to be recognized
for their contributions to the study of aging and the development of
potential new therapies for the treatment of age-related diseases:

  • Dr. Pinchas Cohen was a featured lecturer at the American
    Physiological Society’s November 2016 Meeting on The Integrative
    Biology of Exercise: “Mitochondrial Peptides Regulate Energy
    Homeostasis” in Phoenix, AZ.
  • Dr. Nir Barzilai was the keynote speaker at the 8th
    International Congress of the Growth Hormone Research Society and IGF
    Society in Tel Aviv, Israel in November 2016. He was also a featured
    speaker on the topic of longevity at the November 2016 TEDMED
    conference in Palm Springs, CA. In December 2016, he was a panelist at
    The Economist’s symposium “The Business of Longevity” in San
    Francisco, CA.

Fourth Quarter 2016 Financial Highlights

  • Cash and Investments. CohBar had cash and investments of
    $8,686,420 on December 31, 2016, compared to $10,291,487 on December
    31, 2015. With the cash proceeds received from the exercise of
    warrants that took place in the first week of January 2017, CohBar
    began the year with cash and investments of approximately $11.1
    million.
  • RD Expenses. Research and development expenses were
    $960,390 in the three months ended December 31, 2016 compared to
    $709,146 in the prior year period, a $251,244 increase. The increase
    in research and development expenses was due primarily to the costs
    associated with the Company’s IND-enabling activities and an increase
    in salary, benefits and stock-based compensation due to the expansion
    of its scientific staff.
  • GA Expenses. General and administrative expenses were
    $717,054 in the three months ended December 31, 2016 compared to
    $440,321 in the prior year period, a $276,733 increase. The increase
    in general and administrative expenses was primarily due to an
    increase in salary, benefits and stock-based compensation from the
    expansion of the Company’s executive team with the addition of its new
    Chief Executive Officer and Director of Investor Relations and the
    timing of a bonus accrued in the current year quarter with no
    corresponding expense in the prior year period.
  • Net Loss. For the three months ended December 31, 2016, net
    loss was $1,677,148 or $0.05 per share basic and diluted, compared to
    a net loss of $1,150,160, or $0.04 per share basic and diluted, for
    the three months ended December 31, 2015.

Investor Conference Call Information:
Date: March 22, 2017
Time: 2:00
p.m. (PDT)
Dial-in U.S. and Canada: 1-888-287-5516
Dial-in
International: 1-719-457-2683
Conference ID# 3409008

An audio recording of the call will be available beginning at 5:00 p.m.
(PDT) on March 22, 2017, through 9:00 p.m. (PDT) on March 29, 2017. To
access the recording please dial 1-844-512-2921 in the U.S. and Canada
or 1-412-317-6671 internationally and reference Conference ID# 3409008.

About CohBar’s Preclinical Development Program

CohBar’s lead preclinical development program is based on MOTS-c, a
mitochondrial-derived peptide discovered in 2012 by the Company’s
founders and their academic collaborators, whose research has shown that
MOTS-c plays a significant role in the regulation of metabolism. The
Company has developed optimized analogs of the MOTS-c peptide, CB4209
and CB4211, which have demonstrated significant therapeutic potential in
preclinical models of obesity and nonalcoholic steatohepatitis (NASH).
CohBar is currently advancing these drug candidates through IND-enabling
activities with plans to initiate clinical trials of the final candidate
in early 2018.

About CohBar

CohBar (OTCQX: CWBR and TSXV: COB.U) is a preclinical stage
biotechnology company focused on the research and development of
mitochondria based therapeutics (MBTs), an emerging class of drugs for
the treatment of age-related diseases. MBTs originate from the discovery
by CohBar’s founders of a novel group of peptides within the
mitochondrial genome which regulate metabolism and cell death, and whose
biological activity declines with age. CohBar’s efforts focus on the
development of these mitochondrial-derived peptides (MDPs) into
clinically relevant MBTs that offer the potential to address a broad
range of age-related diseases, including obesity, fatty liver disease
(NASH), type 2 diabetes, cancer, cardiovascular and neurodegenerative
diseases. To date, the Company and its founders have discovered more
than 50 biologically active mitochondrial peptides.

For additional company information, please visit www.cohbar.com.

Forward-Looking Statements

This news release contains forward-looking statements (statements which
are not historical facts) within the meaning of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
CohBar’s plans and expectations for its CB4209 and CB4211 candidate
program, including anticipated timing and results of IND-enabling
activities, regulatory submissions and initiation of clinical trials,
statements regarding the therapeutic potential of these and other
mitochondria based therapeutics, and the potential for additional
discoveries, and expectations regarding future patent applications.
Forward-looking statements are based on current expectations, estimates
and projections that involve a number of risks and uncertainties that
could cause actual results to differ materially from those anticipated
by CohBar. These risks and uncertainties include, among other things,
the uncertainties inherent in research and development, including the
ability to meet anticipated commencement and completion dates for
IND-enabling and initial clinical studies, as well as the possibility of
unfavorable study results, including unfavorable new data and additional
analyses of existing data; risks associated with initial data, including
the risk that results of additional pre-clinical or clinical studies may
be different from (including less favorable than) the earlier data
results and may not support further clinical development; whether and
when any investigational new drug application may be filed with
regulatory authorities for CB4209 or CB4211; whether and when regulatory
authorities may approve any such applications, and other decisions by
regulatory authorities that could affect the availability or commercial
potential of CB4209 or CB4211. Additional risks and uncertainties
include CohBar’s ability to retain key personnel, expand its research
operations, and obtain financing necessary to continue its operations
and fund its candidate programs. Additional assumptions, risks and
uncertainties are described in detail in our registration statements,
reports and other filings with the Securities and Exchange Commission
and applicable Canadian securities regulators, which are available on
our website, and at www.sec.gov or www.sedar.com.

You are cautioned that such statements are not guarantees of future
performance and that our actual results may differ materially from those
set forth in the forward-looking statements. The forward-looking
statements and other information contained in this news release are made
as of the date hereof and CohBar does not undertake any obligation to
update publicly or revise any forward-looking statements or information,
whether as a result of new information, future events or otherwise,
unless so required by applicable securities laws.

Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.

 

CohBar, Inc.

Balance Sheets

(unaudited)

 

 

As of

December 31, 2016

 

December 31, 2015

 

ASSETS

Current assets:

Cash

$

3,257,458

$

4,803,687

Investments

5,428,962

5,487,800

Subscription receivable

522,326

Prepaid expenses and other current assets

 

110,822

 

88,223

Total current assets

9,319,568

10,379,710

Property and equipment, net

230,512

199,575

Other assets

 

36,810

 

20,492

Total assets

$

9,586,890

$

10,599,777

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable

$

103,294

$

209,730

Accrued liabilities

132,780

155,713

Accrued payroll and other compensation

447,641

217,250

Note payable, net of debt discount of $59 and $0 as of December 31,
2016 and 2015, respectively

 

205,201

 

Total current liabilities

888,916

582,693

Note payable, net of debt discount of $0 and $255 as of December 31,
2016 and 2015, respectively

 

 

205,005

Total liabilities

 

888,916

 

787,698

 

Commitments and contingencies

 

Stockholders’ equity:

Preferred stock, $0.001 par value, Authorized 5,000,000 shares;

No shares issued and outstanding as of December 31, 2016 and
December 31, 2015, respectively

Common stock, $0.001 par value, Authorized 75,000,000 shares;

Issued and outstanding 34,807,881 shares as of December 31, 2016 and
32,320,891 as of December 31, 2015

34,808

32,321

Additional paid-in capital

23,072,702

18,114,295

Accumulated deficit

 

(14,409,536)

 

(8,334,537)

Total stockholders’ equity

 

8,697,974

 

9,812,079

Total liabilities and stockholders’ equity

$

9,586,890

$

10,599,777

 

 

CohBar, Inc.

Statements of Operations

(unaudited)

 

 

For The Three Months Ended December 31,

 

For The Years Ended December 31,

 

2016

 

 

2015

 

2016

 

 

2015

 

Revenues

$

$

$

$

 

Operating expenses:

Research and development

960,390

709,146

3,606,515

1,966,221

General and administrative

 

717,054

 

440,321

 

2,470,062

 

1,908,080

Total operating expenses

 

1,677,444

 

1,149,467

 

6,076,577

 

3,874,301

Operating loss

 

(1,677,444)

 

(1,149,467)

 

(6,076,577)

 

(3,874,301)

 

Other income (expense):

Interest income

2,296

1,112

9,368

4,762

Interest expense

(1,951)

(1,756)

(7,594)

(7,022)

Other expense

(1,453)

Amortization of debt discount

 

(49)

 

(49)

 

(196)

 

(196)

Total other income (expense)

 

296

 

(693)

 

1,578

 

(3,909)

Net loss

$

(1,677,148)

$

(1,150,160)

$

(6,074,999)

$

(3,878,210)

Basic and diluted net loss per share

$

(0.05)

$

(0.04)

$

(0.18)

$

(0.12)

Weighted average common shares outstanding – basic and diluted

 

33,881,454

 

32,320,891

 

33,402,339

 

32,044,274

Copyright © 2017 Businesswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Article source: http://www.otcmarkets.com/stock/CWBR/news?id=154015

Air Canada (ACDVF: OTCQX International Premier) | Media Advisory

MONTREAL, March 22, 2017 /CNW/ – Michael Rousseau, Executive Vice President and Chief Financial Officer, will present at the Desjardins Industrials, Telecom Consumer Conference on Monday, March 27, 2017 at the Centre Mont-Royal in Montreal.

 

 

SOURCE Air Canada

Article source: http://www.otcmarkets.com/stock/ACDVF/news?id=153988

Bunk Beds